Skip to main content
Journal ArticleOPEN ACCESS

Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination

  • Alislambouli M
  • Veras Victoria A
  • Matta J
  • et al.
eJHaem (2022) 3(1) 207-210
DOI: 10.1002/jha2.342
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease and has occasionally been described after vaccination, especially against viral agents. We present a case of a patient who presents with the classic pentad of TTP a few days after receiving the first dose of the mRNA Pfizer COVID‐19 vaccine. To our knowledge, this is the second report of a de novo TTP following mRNA Pfizer COVID‐19 vaccination.

Cite

CITATION STYLE

APA

Alislambouli, M., Veras Victoria, A., Matta, J., & Yin, F. (2022). Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination. EJHaem, 3(1), 207–210. https://doi.org/10.1002/jha2.342

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free